Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bexarotene for remyelination in relapsing-remitting multiple sclerosis
ISRCTN14265371Phase 2Completed
- Sponsor
- Cambridge University Hospitals NHS Foundation trust & University of Cambridge (Comprehensive)
- Start
- Jan 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 2, randomised trial in multiple sclerosis (MS) comparing Bexarotene with Placebo (2 arms). Primary endpoint: Safety and tolerability. Started Jan 2017; status: completed.
02
Drugs
bexarotene
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on ISRCTN14265371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN14265371.